Bolanle Akinlade (B Akinlade)

Publication Activity (10 Years)

Years Active: 2019-2020
Publications (10 Years): 4

Top Topics

Top Venues

The British journal of dermatology

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

M J Cork, D Thaçi, L F Eichenfield, Peter D Arkwright, X Sun, Z Chen, Bolanle Akinlade, S Boklage, I Guillemin, M P Kosloski, M A Kamal, J T O'Malley, N Patel, N M H Graham, Ashish Bansal
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. The British journal of dermatology 184 (5) (2020)
Bolanle Akinlade, Emma Guttman-Yassky, Marjolein de Bruin-Weller, E L Simpson, Andrew Blauvelt, M J Cork, E Prens, P Asbell, E Akpek, J Corren, C Bachert, I Hirano, J Weyne, A Korotzer, Z Chen, T Hultsch, X Zhu, J D Davis, L Mannent, J D Hamilton, A Teper, H Staudinger, E Rizova, G Pirozzi, N M H Graham, B Shumel, M Ardeleanu, A Wollenberg
Conjunctivitis in dupilumab clinical trials. The British journal of dermatology 181 (3) (2019)
Lawrence F Eichenfield, Thomas Bieber, Lisa A Beck, Eric Lawrence Simpson, Diamant Thaçi, Marjolein de Bruin-Weller, Mette Deleuran, Jonathan Ian Silverberg, Carlos Ferrandiz, Regina Fölster-Holst, Zhen Chen, Neil M H Graham, Gianluca Pirozzi, Bolanle Akinlade, George D Yancopoulos, Marius Ardeleanu
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American journal of clinical dermatology 20 (3) (2019)
M J Cork, D Thaçi, L F Eichenfield, Peter D Arkwright, T Hultsch, J D Davis, Y Zhang, X Zhu, Z Chen, M Li, M Ardeleanu, A Teper, Bolanle Akinlade, A Gadkari, Laurent Eckert, M A Kamal, M Ruddy, N M H Graham, G Pirozzi, N Stahl, A T DiCioccio, Ashish Bansal
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. The British journal of dermatology 182 (1) (2019)